Company
6 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
JUL 29, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
This is an FDA supplemental approval action establishing a Risk Evaluation and Mitigation Strategy (REMS) for mycophenolate mofetil; it does not report clinical trial outcomes or comparative efficacy.
JUN 25, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval for piroxicam labeling changes; does not contain clinical trial data or efficacy evidence.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of a REMS (Risk Evaluation and Mitigation Strategy) for hydrocodone bitartrate and ibuprofen combination tablets; regulatory action does not report clinical trial data or efficacy evidence.
JUN 8, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
This is an FDA supplemental approval action for labeling of a generic losartan potassium formulation; it documents a regulatory decision, not clinical trial evidence.
APR 21, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
This is an FDA supplemental approval for a labeling change to levetiracetam oral solution; it documents a regulatory action, not clinical trial evidence.
APR 2, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval for gabapentin labeling changes; describes a regulatory action, not clinical evidence of efficacy or safety.